scholarly journals Healthcare utilization and direct medical cost in the years during and after cancer diagnosis in patients with type 2 diabetes mellitus

2020 ◽  
Vol 11 (6) ◽  
pp. 1661-1672
Author(s):  
Tingting Wu ◽  
Fan Yang ◽  
Wendy Wing Lok Chan ◽  
Cindy Lo Kuen Lam ◽  
Carlos King Ho Wong
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Direct Medical Cost ◽  
Healthcare Utilization ◽  
Cancer Diagnosis ◽  
Medical Cost ◽  
After Cancer

scholarly journals How Do Type 2 Diabetes Mellitus-Related Chronic Complications Impact Direct Medical Cost in Four Major Cities of Urban China?

2009 ◽  
Vol 12 (6) ◽  
pp. 923-929 ◽  
Author(s):  
Weibing Wang ◽  
Chao Wei Fu ◽  
Chang Yu Pan ◽  
Weiqing Chen ◽  
Siyan Zhan ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Direct Medical Cost ◽  
Medical Cost ◽  
Urban China ◽  
Chronic Complications

scholarly journals Direct Medical Cost of Type 2 Diabetes Mellitus and Its Associated Complications in Indonesia

2022 ◽  
Vol 28 ◽  
pp. 82-89
Author(s):  
Budi Hidayat ◽  
Royasia Viki Ramadani ◽  
Achmad Rudijanto ◽  
Pradana Soewondo ◽  
Ketut Suastika ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Direct Medical Cost ◽  
Medical Cost

scholarly journals The direct medical cost of type 2 diabetes mellitus in South Africa: a cost of illness study

2019 ◽  
Vol 12 (1) ◽  
pp. 1636611 ◽  
Author(s):  
Agnes Erzse ◽  
Nicholas Stacey ◽  
Lumbwe Chola ◽  
Aviva Tugendhaft ◽  
Melvyn Freeman ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
South Africa ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Direct Medical Cost ◽  
Cost Of Illness ◽  
Medical Cost ◽  
Illness Study ◽  
Cost Of Illness Study

scholarly journals Direct medical costs of type 2 diabetes mellitus in the Philippines: findings from two hospital databases and physician surveys

BMJ Open ◽  
2021 ◽  
Vol 11 (10) ◽  
pp. e049737
Author(s):  
Cecilia Jimeno ◽  
Rosa Allyn Sy ◽  
Pepito De La Pena ◽  
Chritopher Cipriano ◽  
Rima Tan ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Medical Cost ◽  
Outpatient Care ◽  
Good Control ◽  
The Philippines ◽  
Poor Control ◽  
Control Range

ObjectiveTo estimate the annual direct medical cost of type 2 diabetes mellitus (T2DM) in hospitals and outpatient care clinics from a healthcare payer perspective in the Philippines.Design and participants(1) A review of electronic hospital records of people with T2DM in two tertiary hospitals—Ospital ng Makati (OsMak) and National Kidney and Transplant Institute (NKTI) and (2) a cross-sectional survey with 50 physicians providing outpatient care for people with T2DM.SettingPrimary, secondary and tertiary healthcare facilities in Metro Manila.Outcome measuresCost of managing T2DM and its related complications in US dollars (USD) in 2016.ResultsA total of 1023 and 1378 people were identified in OsMak and NKTI, with a complication rate of 66% and 74%, respectively. In both institutions, the average annual cost per person was higher if individuals were diagnosed with any complication (NKTI: US$3226 vs US$2242 and OsMak: US$621 vs US$127). Poor diabetes control was estimated to incur higher per person cost than good control in both public outpatient care (poor control, range: US$727 to US$2463 vs good control, range: US$614 to US$1520) and private outpatient care (poor control, range: US$848 to US$2507 vs good control, range: US$807 to US$1603).ConclusionThe results highlight the high direct medical cost resulting from poor diabetes control and the opportunity for cost reduction by improving control and preventing its complications.

scholarly journals Type 2 Diabetes Mellitus Intersects With Pancreatic Cancer Diagnosis and Development

2021 ◽  
Vol 11 ◽  
Author(s):  
Xiaoye Duan ◽  
Weihao Wang ◽  
Qi Pan ◽  
Lixin Guo
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Pancreatic Cancer ◽  
Type 2 Diabetes Mellitus ◽  
Cancer Diagnosis ◽  
Complex Diabetes ◽  
The Relationship ◽  
Early Manifestation ◽  
New Onset

The relationship between type 2 diabetes mellitus (T2DM) and pancreatic cancer (PC) is complex. Diabetes is a known risk factor for PC, and new-onset diabetes (NOD) could be an early manifestation of PC that may be facilitate the early diagnosis of PC. Metformin offers a clear benefit of inhibiting PC, whereas insulin therapy may increase the risk of PC development. No evidence has shown that novel hypoglycemic drugs help or prevent PC. In this review, the effects of T2DM on PC development are summarized, and novel strategies for the prevention and treatment of T2DM and PC are discussed.

The burden of hypoglycemia on healthcare utilization, costs, and quality of life among type 2 diabetes mellitus patients

2012 ◽  
Vol 26 (5) ◽  
pp. 399-406 ◽  
Author(s):  
Setareh A. Williams ◽  
Lizheng Shi ◽  
Susan K. Brenneman ◽  
Jonathan C. Johnson ◽  
Jessica C. Wegner ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Healthcare Utilization
Sign in / Sign up

Export Citation Format

Share Document